Glaxosmithkline Plc Adr Stock Z Score

GSK Stock

USD 36.17 0.38 1.04%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Valuation analysis.

At this time, GlaxoSmithKline PLC's Return On Capital Employed is quite stable compared to the past year. Capital Expenditure Coverage Ratio is expected to rise to 2.69 this year, although the value of Capital Stock will most likely fall to about 1.3 B. At this time, GlaxoSmithKline PLC's Discontinued Operations is quite stable compared to the past year. Extraordinary Items is expected to rise to about 12.7 B this year, although the value of Gross Profit will most likely fall to about 14.6 B.

GlaxoSmithKline PLC ADR Company Z Score Analysis

GlaxoSmithKline PLC's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

GlaxoSmithKline Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for GlaxoSmithKline PLC is extremely important. It helps to project a fair market value of GlaxoSmithKline Stock properly, considering its historical fundamentals such as Z Score. Since GlaxoSmithKline PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GlaxoSmithKline PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GlaxoSmithKline PLC's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Treasury Stock	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Cash And Equivalents
Total Assets		0.67	0.89	0.22	0.15	0.97	0.81	0.71	0.61	0.71	0.3	0.87	0.46	0.93	-0.32	0.28	0.47	0.28	-0.19	0.78	-0.68	0.72	0.61	0.5	0.68	-0.27
Total Stockholder Equity	0.67		0.57	-0.47	0.45	0.49	0.5	0.38	0.21	0.38	0.88	0.46	0.31	0.66	-0.31	0.13	0.42	0.16	0.1	0.79	-0.32	0.73	0.76	0.42	0.83	-0.5
Net Debt	0.89	0.57		0.3	0.09	0.88	0.74	0.66	0.84	0.66	0.24	0.79	0.63	0.84	-0.11	0.25	0.51	0.19	0.0	0.67	-0.58	0.78	0.51	0.59	0.66	-0.17
Accounts Payable	0.22	-0.47	0.3		-0.45	0.4	0.22	0.36	0.49	0.36	-0.72	0.29	0.23	0.12	0.21	0.02	0.13	-0.09	-0.21	-0.13	-0.17	-0.1	-0.3	0.11	-0.34	0.22
Short Term Investments	0.15	0.45	0.09	-0.45		0.12	0.22	0.07	-0.08	0.07	0.44	-0.16	-0.25	0.08	-0.53	0.2	0.18	0.28	0.23	0.56	-0.31	0.07	0.67	-0.14	0.63	-0.4
Total Liab	0.97	0.49	0.88	0.4	0.12		0.81	0.76	0.67	0.76	0.08	0.83	0.45	0.85	-0.3	0.29	0.43	0.29	-0.21	0.7	-0.73	0.6	0.54	0.44	0.59	-0.23
Total Current Assets	0.81	0.5	0.74	0.22	0.22	0.81		0.89	0.62	0.89	0.13	0.7	0.54	0.79	-0.13	-0.01	0.23	0.19	-0.16	0.52	-0.56	0.4	0.52	0.34	0.52	0.08
Capital Stock	0.71	0.38	0.66	0.36	0.07	0.76	0.89		0.53	1.0	-0.06	0.48	0.69	0.57	0.13	-0.3	0.09	0.06	-0.12	0.32	-0.44	0.2	0.35	0.17	0.27	-0.09
Short Term Debt	0.61	0.21	0.84	0.49	-0.08	0.67	0.62	0.53		0.53	-0.03	0.65	0.56	0.65	0.11	0.25	0.53	-0.09	0.14	0.33	-0.3	0.56	0.21	0.53	0.36	0.17
Common Stock	0.71	0.38	0.66	0.36	0.07	0.76	0.89	1.0	0.53		-0.06	0.48	0.69	0.57	0.13	-0.3	0.09	0.06	-0.12	0.32	-0.44	0.2	0.35	0.17	0.27	-0.09
Retained Earnings	0.3	0.88	0.24	-0.72	0.44	0.08	0.13	-0.06	-0.03	-0.06		0.21	0.01	0.4	-0.32	0.2	0.38	0.04	0.21	0.61	-0.02	0.62	0.6	0.34	0.72	-0.35
Intangible Assets	0.87	0.46	0.79	0.29	-0.16	0.83	0.7	0.48	0.65	0.48	0.21		0.37	0.96	-0.27	0.4	0.45	0.23	-0.3	0.61	-0.56	0.72	0.38	0.57	0.5	0.11
Long Term Debt	0.46	0.31	0.63	0.23	-0.25	0.45	0.54	0.69	0.56	0.69	0.01	0.37		0.42	0.63	-0.47	-0.06	-0.2	0.09	0.02	-0.04	0.32	-0.06	0.23	0.09	0.07
Good Will	0.93	0.66	0.84	0.12	0.08	0.85	0.79	0.57	0.65	0.57	0.4	0.96	0.42		-0.3	0.37	0.52	0.23	-0.15	0.75	-0.6	0.76	0.57	0.57	0.68	0.0
Property Plant Equipment	-0.32	-0.31	-0.11	0.21	-0.53	-0.3	-0.13	0.13	0.11	0.13	-0.32	-0.27	0.63	-0.3		-0.65	-0.35	-0.59	0.31	-0.66	0.57	-0.32	-0.67	-0.18	-0.58	0.36
Current Deferred Revenue	0.28	0.13	0.25	0.02	0.2	0.29	-0.01	-0.3	0.25	-0.3	0.2	0.4	-0.47	0.37	-0.65		0.7	0.17	0.22	0.57	-0.42	0.46	0.46	0.36	0.49	-0.11
Net Receivables	0.47	0.42	0.51	0.13	0.18	0.43	0.23	0.09	0.53	0.09	0.38	0.45	-0.06	0.52	-0.35	0.7		-0.17	0.43	0.65	-0.23	0.59	0.61	0.48	0.53	-0.3
Treasury Stock	0.28	0.16	0.19	-0.09	0.28	0.29	0.19	0.06	-0.09	0.06	0.04	0.23	-0.2	0.23	-0.59	0.17	-0.17		-0.49	0.37	-0.78	0.19	0.33	0.12	0.34	-0.16
Net Tangible Assets	-0.19	0.1	0.0	-0.21	0.23	-0.21	-0.16	-0.12	0.14	-0.12	0.21	-0.3	0.09	-0.15	0.31	0.22	0.43	-0.49		0.06	0.21	0.01	0.17	-0.02	0.14	-0.12
Long Term Investments	0.78	0.79	0.67	-0.13	0.56	0.7	0.52	0.32	0.33	0.32	0.61	0.61	0.02	0.75	-0.66	0.57	0.65	0.37	0.06		-0.67	0.73	0.89	0.46	0.92	-0.48
Short Long Term Debt	-0.68	-0.32	-0.58	-0.17	-0.31	-0.73	-0.56	-0.44	-0.3	-0.44	-0.02	-0.56	-0.04	-0.6	0.57	-0.42	-0.23	-0.78	0.21	-0.67		-0.38	-0.59	-0.27	-0.56	0.22
Long Term Debt Total	0.72	0.73	0.78	-0.1	0.07	0.6	0.4	0.2	0.56	0.2	0.62	0.72	0.32	0.76	-0.32	0.46	0.59	0.19	0.01	0.73	-0.38		0.56	0.77	0.77	-0.29
Capital Surpluse	0.61	0.76	0.51	-0.3	0.67	0.54	0.52	0.35	0.21	0.35	0.6	0.38	-0.06	0.57	-0.67	0.46	0.61	0.33	0.17	0.89	-0.59	0.56		0.35	0.87	-0.55
Net Invested Capital	0.5	0.42	0.59	0.11	-0.14	0.44	0.34	0.17	0.53	0.17	0.34	0.57	0.23	0.57	-0.18	0.36	0.48	0.12	-0.02	0.46	-0.27	0.77	0.35		0.54	-0.05
Net Working Capital	0.68	0.83	0.66	-0.34	0.63	0.59	0.52	0.27	0.36	0.27	0.72	0.5	0.09	0.68	-0.58	0.49	0.53	0.34	0.14	0.92	-0.56	0.77	0.87	0.54		-0.39
Cash And Equivalents	-0.27	-0.5	-0.17	0.22	-0.4	-0.23	0.08	-0.09	0.17	-0.09	-0.35	0.11	0.07	0.0	0.36	-0.11	-0.3	-0.16	-0.12	-0.48	0.22	-0.29	-0.55	-0.05	-0.39

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict GlaxoSmithKline PLC

According to the company's disclosures, GlaxoSmithKline PLC ADR has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.

GlaxoSmithKline PLC ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GlaxoSmithKline PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GlaxoSmithKline PLC's managers, analysts, and investors.

Environmental

Governance

Social

GlaxoSmithKline PLC Institutional Holders

Institutional Holdings refers to the ownership stake in GlaxoSmithKline PLC that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of GlaxoSmithKline PLC's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing GlaxoSmithKline PLC's value.

		Shares
Eversept Partners, Llc	2024-09-30	4.1 M
Equity Investment Corp	2024-12-31	4 M
Arrowstreet Capital Limited Partnership	2024-09-30	3.9 M
Grantham, Mayo, Van Otterloo & Co., Llc	2024-09-30	3.7 M
Hotchkis & Wiley Capital Management Llc	2024-09-30	3.5 M
Camber Capital Management Llc	2024-09-30	3 M
Dimensional Fund Advisors, Inc.	2024-09-30	2.6 M
Hsbc Holdings Plc	2024-09-30	2.6 M
Renaissance Technologies Corp	2024-09-30	2.3 M
Dodge & Cox	2024-09-30	68.1 M
Fmr Inc	2024-09-30	29 M

GlaxoSmithKline Fundamentals

	Return On Equity	0.23
	Return On Asset	0.0693
	Profit Margin	0.08 %
	Operating Margin	0.10 %
	Current Valuation	90.03 B
	Shares Outstanding	2.04 B
	Shares Owned By Insiders	0.12 %
	Shares Owned By Institutions	16.99 %
	Number Of Shares Shorted	17.43 M
	Price To Earning	11.80 X
	Price To Book	4.34 X
	Price To Sales	2.35 X
	Revenue	30.33 B
	Gross Profit	22.53 B
	EBITDA	9.14 B
	Net Income	4.93 B
	Cash And Equivalents	3.72 B
	Cash Per Share	0.32 X
	Total Debt	18.02 B
	Debt To Equity	0.98 %
	Current Ratio	1.43 X
	Book Value Per Share	3.35 X
	Cash Flow From Operations	6.77 B
	Short Ratio	4.24 X
	Earnings Per Share	1.55 X
	Price To Earnings To Growth	0.81 X
	Target Price	43.42
	Beta	0.34
	Market Capitalization	73.82 B
	Total Asset	59.01 B
	Retained Earnings	7.24 B
	Working Capital	(2.42 B)
	Current Asset	16.59 B
	Current Liabilities	13.42 B
	Annual Yield	0.04 %
	Five Year Return	5.32 %
	Net Asset	59.01 B
	Last Dividend Paid	0.61

About GlaxoSmithKline PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Valuation analysis.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.167

Dividend Share

0.61

Earnings Share

1.55

Revenue Per Share

15.392

Quarterly Revenue Growth

0.008

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Glaxosmithkline Plc Adr Stock Z Score

GlaxoSmithKline PLC ADR Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

GlaxoSmithKline Z Score Driver Correlations

GlaxoSmithKline PLC ESG Sustainability

GlaxoSmithKline PLC Institutional Holders

GlaxoSmithKline Fundamentals

About GlaxoSmithKline PLC Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY